Hearing Loss Treatment Report

www.HearingLossTreatmentReport.com

Phase 1

FX-322 in Sensorineural Hearing Loss [Completed]

CATEGORY:
Clinical Trials

TITLE:
FX-322 in Sensorineural Hearing Loss

INTERVENTION/TREATMENT:

PHASE:

DESCRIPTION:
Condition :   Sensorineural Hearing Loss

Interventions :   Drug: FX-322;   Drug: Placebo

Sponsor :   Frequency Therapeutics

Completed

ID:
NCT03616223

STATUS:

DATE – FIRST POSTED:
Mon, 06 Aug 2018 12:00:00 EDT

DATE – LAST UPDATE POSTED:
03/30/21 06:51AM

DATE – RETRIEVED:
03/30/21 06:51AM

LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT03616223

LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT03616223

Verification of the Efficacy/Safety of the Dual Drug Delivery for Hearing Loss

https://clinicaltrials.gov/ct2/show/NCT04766853

Verification of the Efficacy/Safety of the Dual Drug Delivery for Hearing Loss

Brief Summary:
This study is a prospective, randomized pilot study. To verify an efficacy and safety of the dual drug injectable delivery vehicle, patients who have not responded to the existing standard treatment will be enrolled. Hearing test and endoscopy of tympanic membrane will be conducted after intratympanic treatment for evaluation.

Condition or disease Intervention/treatment Phase
Hearing Loss, Sudden
Hearing Loss Ototoxic
Hearing Loss, Noise-Induced
Meniere Disease
Drug: Dexamethasone
Drug: Hyaluronic acid
Phase 1
Phase 2

Study Design
Go to sections
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Verification of the Efficacy / Safety of the Dual Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (Pilot Study)
Estimated Study Start Date : March 2021
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2022

FX-322 in Adults With Severe Sensorineural Hearing Loss

CATEGORY:
Clinical Trials

TITLE:
FX-322 in Adults With Severe Sensorineural Hearing Loss

INTERVENTION/TREATMENT:

PHASE:

DESCRIPTION:
Conditions :   Hearing Loss, Sensorineural;   Noise Induced Hearing Loss;   Sudden Hearing Loss

Interventions :   Drug: FX-322;   Other: Placebo

Sponsor :   Frequency Therapeutics

Recruiting

ID:
NCT04629664

STATUS:

DATE – FIRST POSTED:
Mon, 16 Nov 2020 12:00:00 EST

DATE – LAST UPDATE POSTED:
11/16/20 07:07AM

DATE – RETRIEVED:
11/16/20 07:07AM

LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT04629664

LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT04629664

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

https://clinicaltrials.gov/ct2/show/NCT04129775?type=Intr&cond=Hearing+Loss&lupd_s=10%2F03%2F2019&lupd_d=14&sort=nwst

Condition :   Sensorineural Hearing Loss

Interventions :   Drug: OTO-413;   Drug: Placebo

Sponsor :   Otonomy, Inc.

Recruiting

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

NCT04129775

Thu, 17 Oct 2019 12:00:00 EDT

Last Update Posted: 10/17/19 08:21AM

https://clinicaltrials.gov/ct2/show/NCT04129775

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

Updated: September 14, 2020
Active, not recruiting

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2020

Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss [Completed]

https://clinicaltrials.gov/ct2/show/NCT02132130?type=Intr&cond=Hearing+Loss&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst

Condition :   Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss

Intervention :   Drug: CGF166

Sponsor :   Novartis Pharmaceuticals

Recruiting

Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss

NCT02132130

Wed, 07 May 2014 12:00:00 EDT

Last Update Posted: 05/13/19 07:50AM

Back to top